Boston Scientific (NYSE:BSX) Director David Habiger Buys 2,100 Shares of Stock

Boston Scientific Corporation (NYSE:BSX) Director David Habiger purchased 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Boston Scientific Stock Up 0.1%

Shares of NYSE BSX opened at $49.35 on Friday. The company has a 50 day simple moving average of $45.75 and a 200 day simple moving average of $60.73. The firm has a market cap of $71.53 billion, a PE ratio of 19.98, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the firm posted $0.75 EPS. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has authorized a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

A number of research firms have commented on BSX. Royal Bank Of Canada reduced their price target on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, July 30th. Raymond James Financial reaffirmed an “outperform” rating and issued a $57.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. TD Cowen reduced their target price on Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Wolfe Research lowered shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Finally, Evercore set a $65.00 price objective on shares of Boston Scientific in a research note on Monday, July 6th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Institutional Investors Weigh In On Boston Scientific

Several large investors have recently added to or reduced their stakes in BSX. Vanguard Group Inc. grew its position in shares of Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after buying an additional 1,436,550 shares during the period. BlackRock Inc. acquired a new position in shares of Boston Scientific during the 2nd quarter valued at $5,534,781,000. State Street Corp boosted its stake in Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after acquiring an additional 920,495 shares in the last quarter. Capital World Investors boosted its stake in Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after acquiring an additional 502,627 shares in the last quarter. Finally, Norges Bank acquired a new stake in Boston Scientific in the fourth quarter worth $2,199,395,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.